Jim Cramer Ties Medtronic Growth Surge to Diabetes Exit and Margin Risks
Medtronic plc reported fiscal first-quarter 2027 revenue near $9.8 billion, up 13.7% organically, with non-GAAP diluted EPS rising 15.1% to $1.45. The company raised its full-year organic revenue-growth forecast to 7.25%-7.75% and increased lower-end non-GAAP EPS guidance to $5.94. It also committed $700 million to Cornerstone Robotics and agreed to invest up to $80 million in Pi-Cardia.